Interstitial Cystitis and Chronic Pelvic Pain Management

Interstitial cystitis (IC), also known as bladder pain syndrome, is a chronic disorder marked by pelvic pain, urinary urgency and frequency in the absence of identifiable infection. Pathophysiology involves urothelial barrier dysfunction, local immune activation, neurogenic inflammation and central sensitisation. Management spans conservative measures such as behavioural modification, bladder training and pelvic floor rehabilitation, to pharmacotherapy targeting neuropathic pain, inflammatory mediators and urothelial repair. In refractory cases, intravesical therapies, neuromodulation and emerging regenerative approaches are employed. A multidisciplinary strategy integrating urology, pain medicine, physiotherapy and psychological support is essential to tailor interventions and improve quality of life.

Research from Nature Portfolio

Urine-based biomarker profiling has advanced non-invasive diagnostics by delineating distinct cytokine and chemokine signatures that distinguish IC subgroups from other urinary disorders and controls, paving the way for algorithmic screening tools. Autologous platelet-rich plasma delivered via serial intravesical injections has demonstrated symptom relief and objective shifts in urinary growth factor levels and matrix-remodelling enzymes in patients unresponsive to standard therapies. Exploratory microbiome studies have revealed specific gut bacterial taxa depleted in IC, implicating a gut–bladder axis and suggesting microbiota-based biomarkers and novel therapeutic targets.

Interstitial Cystitis and Chronic Pelvic Pain Management publication trend

The graph below shows the total number of articles in interstitial cystitis and chronic pelvic pain management across all publications each year (not limited to Nature Index journals).

Technical terms

Urothelium: The specialised epithelial lining of the bladder that provides a barrier and sensory function.

Cytokine/Chemokine: Small signalling proteins that orchestrate immune cell recruitment, inflammation and tissue responses.

Platelet-Rich Plasma: A concentration of a patient’s own platelets in plasma, rich in growth factors that promote tissue repair.

Oxidative Stress: Cellular damage caused by an imbalance between reactive oxygen species production and antioxidant defences.

Central Sensitisation: Enhanced responsiveness of neurons in the central nervous system, contributing to chronic pain amplification.

References

1. Characterization and Therapeutic Potential of Curcumin-Loaded Cerium Oxide Nanoparticles for Interstitial Cystitis Management. Antioxidants (2024).
2. Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. PLOS ONE (2018).
3. The MAPP research network: design, patient characterization and operations. BMC Urology (2014).
4. Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. Scientific Reports (2021).
5. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Scientific Reports (2020).
6. Stool-based biomarkers of interstitial cystitis/bladder pain syndrome. Scientific Reports (2016).